About Us
We are an R&D Firm Specialized in creating Innovative and Disruptive treatments for Skin Cancer
The Problem...
Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC)
are the most common forms of Skin Cancer
​
Basal cell carcinoma typically manifests as small, fleshy bumps or nodules
Squamous cell carcinoma manifests in nodules or red, scaly patches
An estimated 5.4 million cases of BCC & SCC are diagnosed in the U.S. each year
ClearQ™
SKIN CANCER PRODUCT AND DEVICE
Our Solution..is Groundbreaking
We are in a Clinical Trial Phase
We have partnered with a renowned and established cancer hospital to conduct clinical trials that we believe will validate the findings from our in-vitro study and expedite our funding efforts.
In-Vitro Study 2
ClearQ significantly decreased the proliferation of cultured basal-cell carcinoma after 24 Hours
In-Vivo Study*
ClearQ visually eradicated the Small Open Sore, Irritated Patch & Nodules diagnosed as Basal Cell Carcinoma after 5 treatments
* The in vivo study referenced was conducted in-house. We are currently in discussions to conduct a formal study with one of the top Cancer Hospitals to further validate our findings and explore clinical applications.
Proliferation assay
For the proliferation test, first generation basal-cell carcinoma cells were seeded at 300,000 cells per well in 6-well plates and incubated for 24 hours.
After 24 hours, cells were washed in PBS
(Thermo Fisher Scientific, USA) and treated with ClearQ™ with light irradiation, placebo with or without light irradiation, and negative control.
Irradiation was done for 1 hour. Treated cells were incubated for 6, 12 or 24 hours at 37C with 5% CO2 atmosphere and ~95% humidity. Placebo-treated cells and cells treated with cell culture medium were used asnegative controls. All treatments were performed in triplicate.
Following 6-,12- or 24-hour incubation, the cells were washed with PBS (Thermo Fisher Scientific), fixed with 4%paraformaldehyde in PBS, washed with PBS, and stained with 0.1% crystal violet for 20 minutes. Crystal violet binds DNA and therefore its levels are directly proportional to the number of cells in the culture (1, 2).
Regulatory Approval Timeline
Elevating ClearQ:
A Future Powered by Innovation and Partnership
At Anessa, we're not just about creating solutions; we're about envisioning the future. As we continue to advance our product and expand its capabilities, we are excited to share that we are actively engaging with angel investors who see the transformative potential of ClearQ.
These discussions represent more than just financial investment; they are a testament to the belief in our vision and the impact ClearQ aims to have.
​
Stay tuned for updates as we embark on this exciting phase of expansion and partnership.
Ray DiFalco
Founder/President
-
More than 30 years of experience in the Pharmaceutical Industry
-
Extensive experience in bulk and finished product manufacturing
-
Worked with several leading pharmaceutical companies such as:
Merck
Par Pharmaceuticals
Pfizer
Lederle (American Home Products)
​​
-
Mr. DiFalco has B.S. in Chemical Engineering and B.S. in Business Administration from Manhattan College and New York university.
-
Inventor/co-inventor of various patents and publisher numerous papers
Embark on a journey with us to revolutionize the treatment of skin cancer
​
We invite you to connect with us if you're passionate about pioneering innovations and eager to join our mission in transforming the world.
